This challenges the notion that immune dysfunction emerges only in late-stage CRC; instead, in stage II compensatory suppression begins (IL10, LAG3, CD27, FAS, CD8B upregulation), potentially priming the microenvironment for progression. The gene discussed is CD8B; the disease is colorectal carcinoma.